Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 8/20 | 0.32 |
| ▸ | CTSS | P25774 | 7/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19432322 | 0.96 | SLC6A2 (0.32) | PRMT1CTSSPRMT6RETCARM1 | |
| SCHEMBL16129012 | 0.86 | S1PR1 (0.39) | PRMT1CTSSPRMT6CARM1AR | |
| SCHEMBL19432090 | 0.85 | S1PR1 (0.34) | PRMT1CTSSCARM1AR | |
| SCHEMBL16129020 | 0.85 | S1PR1 (0.34) | PRMT1CARM1AR | |
| SCHEMBL16129018 | 0.84 | CARM1 (0.35) | PRMT1PRMT6CARM1ARPRMT8 | |
| SCHEMBL19904785 | 0.84 | AR (0.33) | PRMT1CARM1AR | |
| SCHEMBL16129006 | 0.81 | S1PR1 (0.39) | PRMT1CTSSPRMT6CARM1AR | |
| SCHEMBL16129533 | 0.81 | PRMT1 (0.33) | PRMT1PRMT6CARM1PRMT8 | |
| SCHEMBL16129448 | 0.81 | PRMT1 (0.33) | PRMT1PRMT6CARM1PRMT8 | |
| SCHEMBL16124050 | 0.81 | PRMT1 (0.38) | PRMT1PRMT6CARM1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170283400-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CTSS 3890/4885PRMT6 4/4885 |
| US-20170283400-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CTSS 3890/4885PRMT6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.